Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus HUMATIN.
GENOPTIC vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic